文献速递神经康复

脑小血管病负荷:慢性卒中失语患者命名治疗反应性的独立生物标志物

Cerebral Small Vessel Disease Burden: An Independent Biomarker for Anomia Treatment Responsiveness in Chronic Stroke Patients With Aphasia.
PubMed 文献 · Arch Phys Med Rehabil · 2023-06-07

本研究回顾性分析30例接受命名治疗的慢性卒中失语患者,采用MRI评估脑小血管病(cSVD)负荷。结果显示基线cSVD负荷可独立于人口学和卒中相关因素预测命名治疗反应,低负荷者康复反应更佳,且cSVD负荷与非言语执行功能相关。

要点

  • 基线cSVD负荷可独立预测命名治疗反应,低负荷者反应更佳。
  • cSVD负荷与非言语执行功能相关,与基线语言任务表现无关。
  • cSVD负荷或可用于个体化治疗,如严重cSVD者同时针对语言和非语言认知。

核心结论

  • cSVD负荷是慢性卒中失语患者命名治疗反应性的独立生物标志物。

研究设计与样本

  • 回顾性研究,纳入30例接受命名治疗的慢性卒中失语患者,采用验证的视觉量表评估4种cSVD神经影像标志物并计算总分。

主要发现

  • 基线cSVD负荷独立于人口学和卒中相关因素预测命名治疗反应(β=-6.816e-02,P=.019)。
  • cSVD负荷与基线非言语执行功能高度相关(r=-0.49,P=.005)。
  • cSVD负荷与基线语言任务表现无关联。

关键数值与推荐

  • cSVD神经影像标志物包括白质高信号、血管周围间隙扩大、腔隙和全局皮层萎缩,使用验证的视觉量表评分。
  • 命名治疗为每周2次、每次120分钟,最多12周。
  • 主要结局为治疗探针准确率百分比变化(治疗后减治疗前)。

临床怎么用

  • cSVD负荷可用于区分更可能对命名治疗有反应的患者。
  • 对cSVD负荷严重的患者,治疗参数可个体化,如同时针对语言和非语言认知。

局限性

  • 回顾性研究设计。
  • 样本量较小(N=30)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether MRI-based cerebral small vessel disease (cSVD) burden predicts treatment-induced aphasia recovery in chronic stroke patients above and beyond initial aphasia severity and stroke-lesion volume. DESIGN: Retrospective. Four cSVD neuroimaging markers were rated using validated visual scales: white matter hyperintensities, enlarged perivascular spaces, lacunes, and global cortical atrophy. We also calculated a cSVD total score. We employed linear regression models to model treatment response as a function of cSVD burden. We also ran correlation analyses to determine the association among cSVD burden and pre-treatment linguistic and non-linguistic cognition. SETTING: Research clinic. PARTICIPANTS: The study includes data from 30 chronic stroke patients with aphasia who received treatment for word finding difficulties and completed additional pre-treatment neuroimaging and behavioral assessments (N=30). INTERVENTIONS: 120-minute sessions of anomia treatment 2 times per week for up to 12 weeks. MAIN OUTCOME MEASURES: Change in accuracy on the treatment probes measured as a percentage (ie, change in accuracy percentage score=post-treatment accuracy percentage minus pre-treatment accuracy percentage). RESULTS: Baseline cSVD burden predicted response to anomia treatment independently from demographic and stroke-related factors. Patients with lower cSVD burden exhibited enhanced rehabilitation response compared with those with higher cSVD burden (β=-6.816e-02, P=.019). cSVD burden was highly associated with nonverbal executive function at baseline (r=-0.49, P=.005): patients with lower cSVD burden exhibited higher performance on nonverbal executive function tasks compared with participants with higher cSVD burden. No association was observed among cSVD burden and performance on language tasks at the baseline. CONCLUSIONS: cSVD, a marker of brain reserve and a robust risk factor for post-stroke dementia, may be used as a biomarker for distinguishing patients who are more likely to respond to anomia therapy from those who are less likely to do so and for individualizing treatment parameters (eg, targeting both linguistic and nonlinguistic cognition in severe cSVD).

来源:Arch Phys Med Rehabil,查看原文。版权归原作者所有。

引用

  1. Varkanitsa M, Peñaloza C, Charidimou A, et al. Cerebral Small Vessel Disease Burden: An Independent Biomarker for Anomia Treatment Responsiveness in Chronic Stroke Patients With Aphasia. Arch Phys Med Rehabil. 2023. PMID: 37290492. doi:10.1016/j.apmr.2023.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。